Drug Profile
Nalotimagene carmaleucel - AGC Biologics
Alternative Names: Herpes simplex virus thymidine kinase (HSV-Tk) donor lymphocytes; HSV-Tk; TBI-0301; Thymidine kinase cell therapy - AGC Biologics; TK; TK cell therapy - AGC Biologics; ZalmoxisLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator MolMed
- Developer AGC Biologics
- Class Cell therapies; Gene therapies; Gene-directed enzyme-prodrug therapies; T lymphocyte cell therapies
- Mechanism of Action Gene transference; Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Leukaemia
Most Recent Events
- 01 Mar 2018 Launched for Leukaemia (Adjunctive treatment) in Italy (IV)
- 26 Feb 2018 Launched for Leukaemia (Adjunctive treatment) in Germany (IV) before February 2018
- 25 Jul 2017 Dompe acquires license and distribution rights to thymidine kinase cell therapy in European Economic Area (EEA), and option rights for Australia, Switzerland and Turkey for Haematological malignancies